Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders
|
|
ACCENTIA BIOPHARMACEUTICALS INC (ABPI)
|
Add to portfolio |
|
|
|
| Price: |
$0.00
| | Metrics |
| OS: |
89.8
|
M
| |
|
|
| Market cap: |
$9
|
k
| |
|
|
|
Net debt:
|
$41.4
|
B
| |
|
|
|
EV:
|
$41.4
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($2.0)
|
B
| |
|
|
|
EBIT
|
($1.9)
|
B
| |
|
|
| EPS |
($7,378,198.11)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Sep-30-12 | Sep-30-11 | Sep-30-10 | Sep-30-09 | Sep-30-08 | Sep-30-07 | Sep-30-06 | Sep-30-05 |
| Revenues | 4.1 | 4.0 | 5.4 | 10.6 | 15.9 | 18.3 | 25.1 | 25.2 |
| Revenue growth | 2.5% | -26.1% | -49.3% | -26.0% | -12.9% | -27.0% | -0.5% | -2.9% |
| Cost of goods sold | 2.8 | 2.5 | 2.9 | 7.8 | 9.7 | 8.7 | 8.4 | 8.2 |
| Gross profit | 1.3 | 1.5 | 2.5 | 2.7 | 6.3 | 9.6 | 16.7 | 17.0 |
| Gross margin | 31.7% | 37.1% | 45.8% | 25.8% | 39.8% | 52.3% | 66.5% | 67.3% |
| Sales and marketing | 0.1 | 0.1 | 0.1 | 0.1 | 6.0 | 8.4 | 14.0 | 15.2 |
| Research and development | 5.2 | 2.2 | 1.3 | 1.3 | 8.9 | 15.5 | 14.0 | 9.6 |
| General and administrative | 7.4 | 20.2 | 4.2 | 8.1 | 18.1 | 19.3 | 23.3 | 21.1 |
| EBITA | -7.6 | -20.5 | -2.9 | -6.6 | -25.7 | -38.2 | -34.5 | -29.5 |
| EBITA margin | -187.1% | -519.1% | -54.0% | -62.5% | -161.5% | -209.1% | -137.6% | -116.9% |
| Amortization of intangibles | 0.1 | 0.5 | 0.3 | 0.2 | 1.1 | 1.0 | 2.2 | 2.4 |
| EBIT | -7.7 | -21.0 | -3.2 | -6.8 | -26.8 | -39.3 | -36.6 | -31.9 |
| EBIT margin | -189.6% | -530.7% | -59.9% | -64.7% | -168.2% | -214.8% | -146.1% | -126.7% |
| Pre-tax income | -12.4 | -15.8 | -47.4 | -5.3 | -60.8 | -76.0 | -43.4 | -44.7 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | | 0.0% | 0.0% | 0.0% | 0.0% |
| Earnings from continuing ops | -4.3 | -11.6 | -50.1 | -5.3 | 0.0 | 0.0 | 0.0 | 0.0 |
| Earnings from discontinued ops | | | | 1.7 | | | | |
| Net income | -4.3 | -11.6 | -50.1 | -5.3 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net margin | -106.6% | -292.0% | -936.0% | -49.9% | 0.0% | 0.0% | 0.0% | 0.0% |
| |
| Diluted EPS | ($0.05) | ($0.17) | ($0.86) | | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares outstanding (diluted) | 80.7 | 68.4 | 58.0 | | 45.9 | 34.4 | 27.9 | 5.1 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|